Diuretic Patents (Class 514/869)
  • Patent number: 9938236
    Abstract: The present invention provides novel compounds of formula (I) and methods of use thereof. In certain embodiments, the compounds of the invention are useful as nucleocapsid assembly inhibitors. In other embodiments, the compounds of the invention are useful as pregenomic RNA encapsidation inhibitors of Hepatitis B virus (HBV). In yet other embodiments, the compounds of the invention are useful for the treatment of viral infection, including HBV and related viral infections.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: April 10, 2018
    Assignees: Drexel University, Baruch S. Blumberg Institute, Arbutus Biopharma, Inc.
    Inventors: Xiaodong Xu, Ju-Tao Guo, Tong Xiao, Yanming Du, Timothy Block, Simon David Peter Baugh, Hong Ye
  • Patent number: 9586957
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof: I useful as HIV attachment inhibitors.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: March 7, 2017
    Assignee: ViiV Healthcare UK (No.5) Limited
    Inventors: Tao Wang, Zhiwei Yin, Zhongxing Zhang, John A. Bender, Barry L. Johnson, John F. Kadow, Nicholas A. Meanwell
  • Patent number: 9464079
    Abstract: Methods employing chemiluminescent agents as therapeutically active agents in the treatment of proliferative disorders are disclosed. The chemiluminiscent agents are used in the disclosed method without a therapeutically effective amount of a photosensitizer. Novel chemiluminescent agents having the general formula: are also disclosed, wherein X, Y, Z, R3 and R5-R9 are as defined herein.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: October 11, 2016
    Assignees: Semorex Technologies Ltd., Ariel-University Research and Development Company Ltd.
    Inventors: Bernard S. Green, Galia Luboshits, Michael A. Firer
  • Patent number: 9023893
    Abstract: The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: May 5, 2015
    Assignee: Novartis AG
    Inventors: William Hewitt, Daniel L Vasella, Randy L Webb
  • Patent number: 9023894
    Abstract: The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: May 5, 2015
    Assignee: Novartis AG
    Inventors: William Hewitt, Daniel L Vasella, Randy L Webb
  • Patent number: 8889115
    Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.
    Type: Grant
    Filed: October 9, 2012
    Date of Patent: November 18, 2014
    Assignee: Relypsa, Inc.
    Inventors: Dominique Charmot, Han-Ting Chang, Gerrit Klaerner, Jerry M. Buysse, Mingjun Liu
  • Patent number: 8409561
    Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: April 2, 2013
    Assignee: Relypsa, Inc.
    Inventors: Dominique Charmot, Han-Ting Chang, Mingjun Liu, Futian Liu, Gerrit Klaerner
  • Patent number: 8377911
    Abstract: A compound having the structure formula (I) or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: February 19, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Lin Yan
  • Patent number: 8354394
    Abstract: A compound having the structure (I) wherein R is selected from the group consisting of 1) and 2), or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: January 15, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Christopher Franklin, Ravi Nargund, Michael Man-Chu Lo, Lin Yan, Pei Huo
  • Patent number: 8173596
    Abstract: A method for treating a disorder characterized by salt retention, fluid retention, and combinations thereof. A method for determining the presence of or the progression of a disorder characterized by salt retention, fluid retention, salt loss, fluid loss, and combinations thereof. An immunoassay kit for detecting a level of prouroguanylin in a sample.
    Type: Grant
    Filed: May 16, 2005
    Date of Patent: May 8, 2012
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Michael F. Goy, Nicholas G. Moss, Xun Qian
  • Patent number: 7776319
    Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: August 17, 2010
    Assignee: Relypsa, Inc.
    Inventors: Robert Alpern, Jerry Buysse, Han Ting Chang, Dominique Charmot, Michael James Cope, John Fordtran, Gerrit Klaerner, Eric Connor, Mingjun Liu, Futian Liu, Jun Shao
  • Patent number: 6784179
    Abstract: A compound of formula (I) and salts and solvates thereof, in which: R0 represents hydrogen, halogen or C1-6 alkyl; R1 represents hydrogen, C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, halo C1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl or heteroaryl C1-3alkyl; R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring  attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3 represents hydrogen or C1-3 alkyl, or R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: August 31, 2004
    Assignee: ICOS Corporation
    Inventor: Alain Claude-Marie Daugan
  • Patent number: 6503883
    Abstract: The invention relates to a pharmaceutical preparation, which contains an immunosuppressive active agent in dissolved form in a starch capsule, or hard or soft gelatin capsule which has been coated with one or several polymer films. The invention further relates to a process for the production of the pharmaceutical preparation.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 7, 2003
    Assignee: Novartis AG
    Inventor: Ulrich Posanski
  • Patent number: 6420358
    Abstract: This invention provides methods of increasing urine flow in humans while minimizing the loss of electrolytes or ions, the methods comprising administering to a human in need thereof a combination of N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide (or a pharmaceutically acceptable salt thereof), also known as VPA-985, and one or more diuretic agents, as well as pharmaceutical compositions and kits or packages for such combinations.
    Type: Grant
    Filed: September 25, 2000
    Date of Patent: July 16, 2002
    Assignee: American Cyanamid Company
    Inventors: Evelyn Ellis-Grosse, Gayle P. Orczyk
  • Patent number: 6369059
    Abstract: A compound of formula (I) and salts and solvates thereof, in which: R0 represents hydrogen, halogen or C1-6 alkyl; R1 represents hydrogen, C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl or heteroarylC1-3alkyl; R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring  attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3 represents hydrogen or C1-3 alkyl, or R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: April 9, 2002
    Assignee: ICOS Corporation
    Inventor: Alain Claude-Marie Daugan
  • Patent number: 6329428
    Abstract: The present invention is drawn to a therapeutic drug for micturition disorders and diseases of the lower urinary tract system, containing an organic acid salt of [2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]ethyl]-dimethylsulfonium. The invention enables treatment of diseases of the lower urinary tract system which cause urinary disorders, such as interstitial cystitis and prostatitis, which arise from unelucidated causes and thus are regarded intractable diseases.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: December 11, 2001
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Tamio Yamauchi, Tomohiro Ueda
  • Patent number: 5948799
    Abstract: This invention relates to a method for reducing morbidity and/or mortality in a mammal with congestive heart failure due to non-ischemic etiology comprising administering amlodipine or a pharmaceutically acceptable amlodipine acid addition salt, and, optionally, a diuretic and/or digoxin. The invention further relates to methods for treating patients with congestive heart failure due to non-ischemic etiology, comprising administering a non-ischemic congestive heart failure treating amount of amlodipine or a pharmaceutically acceptable amlodipine salt and, optionally, a diuretic and/or digoxin. The invention also provides a kit which comprises a container means and a) amlodipine and a diuretic, b) amlodipine and digoxin, or c) amlodipine, digoxin and a diuretic; and a kit which comprises a container means and a) amlodipine, an angiotensin converting enzyme (ACE) inhibitor and a diuretic, b) amlodipine, an ACE inhibitor and digoxin, or c) amlodipine, an ACE inhibitor, digoxin and a diuretic.
    Type: Grant
    Filed: March 12, 1997
    Date of Patent: September 7, 1999
    Assignee: Pfizer Inc.
    Inventor: Anne Barbara Cropp
  • Patent number: 5914336
    Abstract: A method of controlling the serum solubility of orally administered torasemide is disclosed. A new crystallin modification of torasemide, called modification III which has significantly higher rates of solubilization than the known crystallin form of torasemide, modification I, is blended with amounts of modification I to produce a preselected level of torasemide in serum at a given time following administration. Compositions containing amounts of modification I and modification III, sufficient to achieve the desired serum levels of torasemide, are also disclosed.
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: June 22, 1999
    Assignee: Boehringer Mannheim GmbH
    Inventor: Bruno Dreckmann-Behrendt
  • Patent number: 5843476
    Abstract: Compositions containing a first dispersion of lipid vesicles which are capable of penetrating into the deep layers of the skin and which contain at least one active agent chosen from lipolytic agents, draining agents and firming agents, for treating these deep layers, and a second dispersion of lipid vesicles which are capable of penetrating into the surface layers of the skin and which contain at least one active agent chosen from cutaneous surface treatment agents, exfoliation agents, smoothing agents and softening agents for the skin, for treating these surface layers, are effective as slimming agents for combating plumpness.
    Type: Grant
    Filed: February 19, 1997
    Date of Patent: December 1, 1998
    Assignee: L'Oreal
    Inventors: Alain Ribier, Jean-Thierry Simonnet, Chantal Fanchon, Evelyne Segot, Herve Cantin
  • Patent number: 5843452
    Abstract: A composition for use in immunosuppression therapy is disclosed. The composition includes an immunosuppressant drug, such as cyclosporin A, and an ethanol extract of the root xylem of Tripterygium wilfordii. The extract is effective alone, or in combination with such an immunosuppressant, in the treatment of transplantation rejection. Also disclosed is a method of immunosuppression that includes administering to a subject a pharmaceutically effective amount of an immunosuppressant drug and an extract of the type above, in an amount effective to potentiate the action of the drug.
    Type: Grant
    Filed: June 2, 1994
    Date of Patent: December 1, 1998
    Assignee: Pharmagenesis, Inc.
    Inventors: Tien-Wen Tao Wiedmann, Jian Wang, Nathan B. Pliam, Hank C. K. Wuh
  • Patent number: 5728678
    Abstract: The present invention provides a composition as well as method for providing nutrition to renal patients. Pursuant to the present invention, the enteral composition includes an effective amount of a protein source including whey protein and free amino acids that provide essential as well as nonessential amino acids. The composition is calorically dense and has a moderate osmolality.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 17, 1998
    Assignee: Nestec Ltd.
    Inventors: Susan Trimbo, Diana Twyman, David Madsen, Shen-Youn Chang, Hugh N. Tucker
  • Patent number: 5668157
    Abstract: Cyanoguanidine compounds of formula (I) and its pharmaceutically acceptable acid addition salts wherein R.sub.1 is hydrogen or methyl; R.sub.2 is C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.3 -C.sub.5 cycloalkyl, C.sub.3 -C.sub.5 cycloalkenyl hydroxy methyl, methoxy-C.sub.1 -C.sub.5 alkyl, or R.sub.1 and R.sub.2 are combined to form a C.sub.3 -C.sub.6 carbocyclic ring; R.sub.3 and R.sub.4 are each independently selected to be hydrogen, C.sub.1 -C.sub.4 alkyl, F, Cl, Br, I or CF.sub.3 ; R.sub.5 is hydrogen, F or Cl; R.sub.6 is hydrogen, --NH.sub.2, --NHCH.sub.3, --NHC.sub.2 H.sub.5, --NHCH(CH.sub.3).sub.2, --N(CH.sub.3).sub.2, --N(C.sub.2 H.sub.5).sub.2, NH(CH.sub.2).sub.m, --OC.sub.1 -C.sub.3 alkyl (where m is 2 or 3), --NHC(O)C.sub.1 -C.sub.3 alkyl, Cl or Br; and n is 0 or 1. The compounds of formula (I) are potassium channel blockers useful in the treatment of cardiovascular disorders such as congestive heart failure and hypertension and as a diuretic.
    Type: Grant
    Filed: June 25, 1996
    Date of Patent: September 16, 1997
    Assignee: Pharmacia & Upjohn Company
    Inventors: Stephen J. Humphrey, Kaushik D. Meisheri, James H. Ludens, Jackson B. Hester, Jr.
  • Patent number: 5565485
    Abstract: Phenoxyphenylacetic acids and derivatives of the general structural formula I ##STR1## have endothelin antagonist activity and are useful in treating cardiovascular disorders, such as hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, benign prostatic hyperplasia, inflammatory diseases including Raynaud's disease and asthma.
    Type: Grant
    Filed: August 22, 1994
    Date of Patent: October 15, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Scott W. Bagley, Theodore P. Broten, Prasun K. Chakravarty, Daljit S. Dhanoa, Kenneth J. Fitch, William J. Greenlee, Nancy J. Kevin, Douglas J. Pettibone, Ralph A. Rivero, Thomas F. Walsh, David L. Williams, Jr., Richard B. Toupence, Jay M. Matthews
  • Patent number: 5508044
    Abstract: A solid oral dosage form comprising diltiazem (or a pharmaceutically acceptable salt thereof) in controlled release form and hydrochlorothiazide in immediate release form. Preferably, the controlled release component comprises a plurality of spheroids comprising diltiazem and a spheronizing agent.
    Type: Grant
    Filed: July 22, 1994
    Date of Patent: April 16, 1996
    Assignee: Euro-Celtique, S.A.
    Inventors: Ian R. Buxton, Adrian Brown, Helen Critchley, Stewart T. Leslie, Sandra T. A. Malkowska, Derek A. Prater, Ronald B. Miller
  • Patent number: 5504099
    Abstract: Aqueous injection solution that is ready-for-injection of a water-soluble, physiologically well-tolerated azosemide salt of an organic amide, which contains an organic solvent and if desired, a physiologically well-tolerated buffer and it concerns a process for the production of such an injection solution in which the salt is dissolved in a mixture which contains water, an organic solvent and, if desired, a physiologically well-tolerated buffer.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: April 2, 1996
    Assignee: Boehringer Mannheim GmbH
    Inventors: Heinrich Woog, Werner Gruber
  • Patent number: 5475031
    Abstract: This invention relates to the use of the succinic acid molecule to stimulate the Citric Acid Cycle in humans and animals and thus relieve those metabolic disorders caused by a deficiency in the Citric Acid Cycle in humans and animals.
    Type: Grant
    Filed: September 3, 1993
    Date of Patent: December 12, 1995
    Inventor: William H. Livingston
  • Patent number: 5422393
    Abstract: A purified naturally occurring natriuretic compound, identified as Natriuretic Hormone, and a method for isolation of the compound. The natriuretic compound has a molecular weight of about 360, a molecular formula of C.sub.21 H.sub.28 O.sub.5 and with a steroidal nucleus. The compound is useful as a diuretic in the treatment of diseases such as heart disease and hypertension.
    Type: Grant
    Filed: October 12, 1993
    Date of Patent: June 6, 1995
    Assignee: Naturon Pharmaceutical Corporation
    Inventors: Neal S. Bricker, William J. Wechter
  • Patent number: 5395836
    Abstract: There is provided a novel xanthine Compound(I) ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and each represent hydroxy-substituted, oxo-substituted or unsubstituted lower alkyl, Y is a single bond or alkylene, and Q is ##STR2## wherein R.sup.3 and R.sup.4 are the same or different and each represent hydrogen or hydroxy, n is 0 or 1; provided that when both of R.sup.3 and R.sup.4 are hydrogen, at least one of R.sup.1 and R.sup.2 is hydroxy-substituted or oxo-substituted lower alkyl; or a pharmaceutically acceptable salt thereof.The xanthine compound has adenosine A.sub.1 receptor antagonizing activity, and thus shows diuretic effect, renal-protecting effect, bronchodilatory effect, cerebral function improving effect and anti-dementia effect.
    Type: Grant
    Filed: April 5, 1994
    Date of Patent: March 7, 1995
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Junichi Shimada, Takashi Kuwabara, Tohru Yasuzawa, Hiroshi Magara, Hiromi Nonaka, Hideaki Kusaka, Fumio Suzuki
  • Patent number: 5364879
    Abstract: The present invention provides a method of medical treatment for a medical condition in a mammal. In this method, a pharmacologically effective amount for treatment of the condition of a trioxolane or a diperoxide of a non-terpene unsaturated hydrocarbon is applied to the mammal. The invention also provides methods of modulating the immune system in a mammal, of treating inflammation of a tissue in a mammal, and of treating bacterial, fungal, protozoal and viral infections in a mammal.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: November 15, 1994
    Assignee: Cliveden Ltd.
    Inventor: Stephen Herman
  • Patent number: 5266596
    Abstract: DL- or L-threo-3-(3,4-dihydroxyphenyl)serine is effective for the treatment of urinary incontinence, shows no side effects such as urine discharge disturbance, palpitation and hypertension, and has low toxicity.
    Type: Grant
    Filed: March 26, 1992
    Date of Patent: November 30, 1993
    Assignee: Sumitomo Pharmaceuticals Co., Ltd.
    Inventors: Kiyoshi Yokokawa, Shuji Takaori
  • Patent number: 5256687
    Abstract: The invention relates to a pharmaceutical composition comprising an angiotensin converting enzyme inhibitor (trandolpril or pamipril) and a loop diuretic (Furosemide or piretanide), and to their use for the treatment of high blood pressure.
    Type: Grant
    Filed: November 19, 1992
    Date of Patent: October 26, 1993
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Reinhard Becker, Rolf Geiger, Rainer Henning, Volker Teetz, Hansjorg Urbach
  • Patent number: 5164401
    Abstract: A method of treating a mammal in need of diruetic treatment by administering an effective diuretic amount of a diuretically active 3,7,9,9-tetrasubstituted 3,7-diazabicyclo[3,3,1]nonane compound, diuretic pharmaceutical compositions containing an effective diuretic amount of a diuretically active 3,7,9,9-tetrasubstituted 3,7-diazabicyclo[3,3,1]nonane compound; and previously unknown diuretically active 3,7,9,9-tetrasubstituted 3,7-diazabicyclo[3,3,1]nonane compounds containing an optionally substituted phenylalkyl group in the 3-position.
    Type: Grant
    Filed: June 17, 1991
    Date of Patent: November 17, 1992
    Assignee: Kali-Chemie Pharma GmbH
    Inventors: Kurt Burow, Gerd Buschmann, Arman Farjam, Ulrich Kuehl, Gerda Varchmin, Deiter Ziegler, Uwe Schoen
  • Patent number: 5143937
    Abstract: Compounds of the formula I ##STR1## where R.sup.1 to R.sup.5 have the meaning indicated, a process for their preparation and their use as medicaments are described. They are effective lipid-lowering agents with antioxidative properties from the benzenesulfonamide series. They do not have hypotensive and diuretic properties.
    Type: Grant
    Filed: February 16, 1990
    Date of Patent: September 1, 1992
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Hans-Jochen Lang, Ernold Granzer, Bela Kerekjarto
  • Patent number: 5132298
    Abstract: A method for improvement in diuresis which comprises administering, to a subject in need of such improvement, a cyclodextrin or a derivative thereof in an amount effective to cause such improvement.
    Type: Grant
    Filed: October 18, 1990
    Date of Patent: July 21, 1992
    Assignee: K.K. Ueno Seiyaku Oyo
    Inventor: Ryuji Ueno
  • Patent number: 5124152
    Abstract: There are described pharmaceutical compositions comprising aqueous solutions of 7 c l r - ,2,3,4-tetrahydro-2-methyl-3-2-methylphenyl)-4-oxo-6-quinazolinesulfonamid e. ethanol and a cosolvent selected from propylene glycol or polyethylene glycols suitable for parenteral administration to a patent suffering from refractory edema.
    Type: Grant
    Filed: January 7, 1991
    Date of Patent: June 23, 1992
    Assignee: Fisons Corporation
    Inventors: Jennifer M. Biringer, Martin L. Eichman
  • Patent number: 5118615
    Abstract: Disclosed is a DNA fragment comprising a base sequence coding for a peptide occurring in human atrium cordis and having diuretic action or a precursor of the peptide, plasmids containing the DNA fragment, microorganisms transformed with the plasmid, and a process for production of the peptide using the transformant.Also disclosed is a new peptide consisting of 126 amino acids occurring in human atrium cordis and a precursor thereof. The peptide has notable diuretic action and hypotensive or antihypertensive actions.
    Type: Grant
    Filed: March 9, 1987
    Date of Patent: June 2, 1992
    Assignee: Suntory Limited
    Inventors: Hisayuki Matsuo, Kenji Kangawa, Yujiro Hayashi, Shinzo Oikawa, Takehiro Oshima, Shoji Tanaka, Hiroshi Nakazato, Yasunori Tawaragi
  • Patent number: 5106610
    Abstract: A method for determining the diuretic potency of candidate drugs as inhibitors of ADH-elicited water channels is disclosed. In a preferred embodiment, such diuretic potency of candidate drugs is determined by suspending vesicles containing ADH water channels in an aqueous suspending medium, incorporating the candidate into the suspension, rapidly changing the pH of the suspending medium and thereafter detecting the proton permeability of the water channels. The proton permeability in the presence of the candidate drug can then be compared to the proton permeability of water channels under similar conditions without the presence of the candidate drug to determine the diuretic potency of the candidate drug to inhibit ADH-elicited water channels.
    Type: Grant
    Filed: December 29, 1989
    Date of Patent: April 21, 1992
    Assignee: Childrens Medical Center Corporation
    Inventors: H. William Harris, Mark L. Zeidel
  • Patent number: 5106630
    Abstract: A purified naturally occurring natriuretic compound, identified as Natriuretic Hormone, and a method for isolation of the compound. The natriuretic compound has a molecular weight of about 360, a molecular formula of C.sub.21 H.sub.28 O.sub.5 and with a steroidal nucleus. The compound is useful as a diuretic in the treatment of diseases such as heart disease and hypertension.
    Type: Grant
    Filed: June 13, 1990
    Date of Patent: April 21, 1992
    Assignee: Neal S. Bricker
    Inventors: Neal S. Bricker, William J. Wechter
  • Patent number: 5104887
    Abstract: High potency carbonic anhydrase inhibitors derived from methazolamide.
    Type: Grant
    Filed: August 28, 1991
    Date of Patent: April 14, 1992
    Assignee: University of Iowa Research Foundation
    Inventors: Ronald D. Schoenwald, Charles F. Barfknecht
  • Patent number: 5100647
    Abstract: Methods for the therapy of cystic fibrosis, Bartter's syndrome, and secretory diarrheas, and for diuretic treatment, by administering to a patient dodecahydro-7,14-methano-2H,6H-di-pyrido[1,2-a:1',2'-e][1,5]diazocine or a pharmaceutically acceptable derivative thereof are disclosed. The formulations include an aerosol formulation comprising the active ingredient in association with an aerosol propellant.
    Type: Grant
    Filed: October 2, 1990
    Date of Patent: March 31, 1992
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Zalman S. Agus, Ellie Kelepouris, Martin Morad
  • Patent number: 5100646
    Abstract: A method of determining the glomerular filtration rate of a subject comprises (1) obtaining a serum sample S.sub.pre and a urine sample U.sub.pre from a subject; (2) administering to the subject an amount of a paramagnetic substance that is filtered by the kidneys and is readily detectable by NMR in serum and urine; (3) allowing for the concentration of the substance to equilibrate between the blood and the extravascular spaces; (4) separating an aliquot of the urine sample v.sub.A and obtaining a serum sample from the subject at the time t.sub.A ; (5) calculating a urine rate (v/a).sub.A from the formula (v/a).sub.A =V.sub.A /a.sub.
    Type: Grant
    Filed: July 25, 1990
    Date of Patent: March 31, 1992
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Peter L. Choyke, Joseph A. Frank, Howard A. Austin
  • Patent number: 5087630
    Abstract: Compounds of formula (Ia), or pharmaceutically acceptable salts or solvates thereof, ##STR1## in which A, together with the nitrogen atom, represents --(CH.sub.2)p--, where p is an integer from 3 to 6, or an optionally substituted tetrahydroisoquinoline ring system;each of R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl C.sub.3-6 cycloalkyl or C.sub.4-12 cycloalkylalkyl, or together form a C.sub.2-6 polymethylene or C.sub.2-6 alkenylene group, optionally substituted with a hetero-atom,R.sub.x is hydrogen, C.sub.1-6 alkyl or phenyl, or together with R.sub.1 forms a --(CH.sub.2).sub.3 -- or --(CH.sub.2).sub.4 -- group; and R comprises a substituted or unsubstituted carbocyclic or heterocyclic aromatic group;and compounds of formula (Ib) ##STR2## in which: R, R.sub.1, R.sub.2 and X are as defined in formula (Ia)R.sub.a is C.sub.1-6 alkyl or phenyl;R.sub.b is hydrogen or together with R.sub.a forms a --(CH.sub.2).sub.
    Type: Grant
    Filed: October 16, 1989
    Date of Patent: February 11, 1992
    Assignee: Dr. Lo. Zambeletti SpA
    Inventors: Roberto Colle, Antonio Pizzi, Geoffrey D. Clarke
  • Patent number: 5011688
    Abstract: A liquid composition for the relief of premenstrual and menstrual discomfort comprising, as active pharmaceutical agents, an effective amount of an analgesic, an antihistamine, and a diuretic, said active agents being dissolved in a liquid vehicle, said composition containing 5-25 percent by volume alcohol and being flavored with active flavoring elements selected from the group consisting of citrus, vanilla, and mint, said active flavoring ingredients being present in an amount sufficient to mask the unpleasant taste of the pharmaceutically active agents.
    Type: Grant
    Filed: May 8, 1990
    Date of Patent: April 30, 1991
    Inventors: Henry D. Calam, Hans A. Schaeffer
  • Patent number: 5010092
    Abstract: Drug treatment therapies and kits for use therewith are disclosed. They involve the use of methimazole and/or its pro-drug carbimazole to reduce nephrotoxic effects of chemical exposure. In one embodiment, a patient receives cisplatin and then is treated with methimazole. The time delay in providing methimazole prevents the methimazole from being substantially expelled by the kidney prior to cisplatin reaching the kidney.
    Type: Grant
    Filed: December 22, 1989
    Date of Patent: April 23, 1991
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Adnan A. Elfarra
  • Patent number: 4981852
    Abstract: A diuretic pharmaceutically acceptable solution of triamterene and solutions of triamterene and hydrochlorothiazide to provide an antihypertensive and diuretic effect for those in need thereof. Triamterene is solubilized in a combination of a glycol and lactic acid present in an amount sufficient to maintain the triamterene in solution. A pharmaceutically acceptable diluent, such as glycerin is also present.
    Type: Grant
    Filed: May 13, 1988
    Date of Patent: January 1, 1991
    Assignee: Multilan AG
    Inventor: Kap S. Ahn
  • Patent number: 4980352
    Abstract: Certain gem-dimethyl substituted bicyclic phenolic pyrazines of formula III possess eukalemic diuretic properties. They are of value in treating those diseases and conditions in which a eukalemic diuretic effect is required, for example in treating edema, hypertension and/or related conditions.
    Type: Grant
    Filed: May 19, 1989
    Date of Patent: December 25, 1990
    Assignee: ICI Americas Inc.
    Inventor: John A. Schwartz
  • Patent number: 4973600
    Abstract: Novel benzodioxole derivative of the formula: ##STR1## wherein R.sup.1 is a lower alkyl group, a lower alkoxy-lower alkyl group, phenyl group or pyridyl group, R.sup.2 is hydrogen atom or a halogen atom and R.sup.3 is hydrogen atom or a lower alkyl group, and a salt thereof are disclosed.Said derivative (I) and a salt thereof have potent diuretic, saluretic and uricosuric activities.
    Type: Grant
    Filed: January 31, 1989
    Date of Patent: November 27, 1990
    Assignee: Tanabe Seiyaku Co., Ltd.
    Inventors: Norio Takamura, Isao Inoue, Masaru Inage, Isao Yamaguchi
  • Patent number: 4968673
    Abstract: The use is described of [1R-[1.alpha.(Z),2.beta.,3.beta.,5.alpha.]]-(+)-7-[5-[[(1,1'-biphenyl)-4-y l]methoxy]-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid or a physiologically acceptable salt, solvate or cyclodextrin complex thereof in the manufacture of medicaments for the therapy or prophylaxis of chronic glomerular diseases including glomerulonephritis, lupus nephritis and systemic lupus erythematosus, renal failure, renal hypertension, hepatorenal syndrome, proteinurea (e.g. albuminurea and microalbuminurea), haemolytic uraemic syndrome and renal impairment following ureteral obstruction.
    Type: Grant
    Filed: June 20, 1989
    Date of Patent: November 6, 1990
    Assignee: Glaxo Group Limited
    Inventor: Patrick P. A. Humphrey
  • Patent number: 4952583
    Abstract: Certain amine containing phenolic pyrazines of formula III possess eukalemic diuretic properties and are of value in treating diseases and conditions in which a eukalemic diuretic effect is required, for example in treating edema, hypertension and/or related conditions.
    Type: Grant
    Filed: May 19, 1989
    Date of Patent: August 28, 1990
    Assignee: ICI Americas Inc.
    Inventor: John A. Schwartz
  • Patent number: RE34222
    Abstract: A pharmaceutical composition comprises magnesium oxide, hydroxide or a non-toxic salt of magnesium in a slow-release carrier; this material may be combined with or co-prescribed with a diuretic or cardiac glycoside or adrenergic receptor blocking agent or a calcium antagonist for the treatment of hypertension or angina pectoris.
    Type: Grant
    Filed: November 28, 1990
    Date of Patent: April 13, 1993
    Inventor: Maurice Bloch